A. Bruce Montgomery, M.D. joined our Board in March 2015. Dr. Montgomery has more than 30 years of drug development, operations and financing experience, including positions at Genentech, Inc., Pathogenesis Corporation, Corus Pharma and Gilead Sciences, Inc. (“Gilead”). From February 2017 to October 2022, he served as Chief Executive Officer and a member of the board of directors of Avalyn Pharma Inc. (formerly Genoa Pharmaceuticals Inc.), a private biotechnology company. From April 2011 to December 2016, he was Chief Executive Officer and a member of the board of directors of Cardeas Pharma Corporation, a private biotechnology company that he founded in 2010. From August 2006 to May 2011, Dr. Montgomery served as Senior Vice President of Gilead and prior to that, served for six years as Chief Executive Officer of Corus Pharma, Inc., a specialized biotechnology company that he founded, which was acquired by Gilead in 2006. While at Gilead, Dr. Montgomery successfully led the development of CAYSTON® as a treatment for cystic fibrosis patients. Dr. Montgomery also served as Executive Vice President of Research and Development at PathoGenesis Corporation until its acquisition by Chiron Corporation in 2000. Dr. Montgomery previously served as a board member for the following publicly traded companies: ZymoGenetics, Inc. (acquired by Bristol-Myers Squibb Company in 2010), Alder BioPharmaceuticals, Inc. (acquired by Lundbeck A/S in 2019) and Cytodyn, Inc. Dr. Montgomery is a board-certified internist and pulmonologist. Dr. Montgomery received his B.S. in chemistry (magna cum laude, Outstanding Chemistry Major (Merck Award)), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. We believe that Dr. Montgomery’s executive leadership experience in pharmaceutical and biotechnology company drug development and his educational background qualify him to serve on our Board.
What is Alan Bruce Montgomery's net worth?
The estimated net worth of Alan Bruce Montgomery is at least $74,125.40 as of December 4th, 2024. Dr. Montgomery owns 9,140 shares of Xencor stock worth more than $74,125 as of May 13th. This net worth approximation does not reflect any other investments that Dr. Montgomery may own. Learn More about Alan Bruce Montgomery's net worth.
How do I contact Alan Bruce Montgomery?
Has Alan Bruce Montgomery been buying or selling shares of Xencor?
Alan Bruce Montgomery has not been actively trading shares of Xencor during the past quarter. Most recently, Alan Bruce Montgomery sold 1,421 shares of the business's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a transaction totalling $38,409.63. Following the completion of the sale, the director now directly owns 9,140 shares of the company's stock, valued at $247,054.20. Learn More on Alan Bruce Montgomery's trading history.
Who are Xencor's active insiders?
Are insiders buying or selling shares of Xencor?
In the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 176,995 shares worth more than $3,994,070.52. The most recent insider tranaction occured on May, 2nd when EVP Nancy Valente sold 4,616 shares worth more than $50,914.48. Insiders at Xencor own 4.8% of the company.
Learn More about insider trades at Xencor. Information on this page was last updated on 5/2/2025.
